Santhera Pharmaceuticals Holding AG (SANN) — Capital Reinvestment Ratio
Santhera Pharmaceuticals Holding AG (SANN) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CHF62.63 Million) in capital expenditures (CHF90.00K). Check SANN tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Santhera Pharmaceuticals Holding AG Capital Reinvestment Ratio (2019–2023)
This chart tracks Santhera Pharmaceuticals Holding AG's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Santhera Pharmaceuticals Holding AG.
Annual Capital Reinvestment Ratio for Santhera Pharmaceuticals Holding AG (2019–2023)
Year-by-year Capital Reinvestment Ratio for Santhera Pharmaceuticals Holding AG from 2019 to 2023. See SANN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.50x | CHF47.27 Million | CHF23.74 Million | ▲ +469.2% |
| 2019 | 0.09x | CHF2.60 Million | CHF229.00K | — |